Welcome to our dedicated page for Cellebrite DI Ltd. SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. (CLBT) called its 2026 Annual General Meeting for September 24, 2026 in Israel and furnished a detailed proxy statement with four voting items: re-electing two Class II directors until 2029, approving CEO Shiven Ramji’s compensation package, approving an updated compensation policy for officers and directors, and re-appointing Kost Forer Gabbay & Kasierer (EY Israel) as independent auditor for 2026 with Board-set fees.
New CEO Shiven Ramji reported that Cellebrite delivered record 2025 financial results, including 21% Annual Recurring Revenue growth and an approximately 34% free cash flow margin, producing “Rule of 55” performance above the company’s stated 45–50 target range. He highlighted acquisitions of Corellium and SCG and new AI-driven products Guardian Investigate and Genesis to expand from digital forensics into a broader investigation intelligence platform.
Ramji also disclosed that second-quarter 2026 ARR fell short of expectations, leading Cellebrite to lower its full-year ARR and revenue outlook while raising its adjusted EBITDA target. The company attributes softer ARR to longer sales cycles, added public-sector procurement complexity and weaker-than-expected expansion from Inseyets conversions, and is responding with sharpened sales execution, tighter resource focus and continued product investment. Shareholders are asked to approve a largely equity-based CEO package (base salary $500,000, 100% target bonus and sizable RSU/PSU grants) and a refreshed, more prescriptive compensation policy that tightens bonus caps, strengthens clawbacks and limits termination and change-of-control benefits.
Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan reported equity compensation and related share withholding. On August 11, 2026, 339,484 ordinary shares were delivered to him upon certification that performance conditions for awards granted on September 19, 2025 were met. On August 12, 2026, 139,713 shares from this vesting were withheld and disposed of to cover his tax obligations at a weighted average price of $15.3861 per share, with individual trades between $15.06 and $15.73. The transactions are reported as directly owned and are not affirmed as executed under a Rule 10b5-1 trading plan.
Cellebrite DI Ltd. reports a leadership transition effective August 13, 2026. By mutual agreement, Thomas E. Hogan ceased serving as Chief Executive Officer and simultaneously resigned from the company’s board of directors. As part of a planned succession, Shiven Ramji was appointed Chief Executive Officer on the same date, providing continuity at the top management level. Mr. Hogan agreed to serve as an advisor to the company for a period of six months following his departure from his executive and board roles, supporting the transition.
Cellebrite DI Ltd. reported higher revenue but lower profitability for the six months ended June 30, 2026. Total revenue rose to $259.4 million from $220.8 million, a 17% increase, driven mainly by subscription revenue of $237.3 million, up 19% year over year. Subscription services reached $194.2 million and term licenses $43.1 million.
Gross profit increased to $211.8 million with an 82% gross margin, down from 84%, as cost of subscription services grew 78% due to higher hosting, support, third-party costs and amortization. Operating expenses rose 23% to $195.7 million, led by higher research and development, sales and marketing, and general and administrative spending, including greater personnel and marketing costs. Net income declined to $17.3 million from $36.9 million, and operating cash flow decreased to $37.5 million from $53.5 million.
The balance sheet remains strong. Cash, cash equivalents, short‑term deposits and marketable securities totaled $545.7 million as of June 30, 2026, compared with $535.0 million at year‑end 2025, with no credit facilities outstanding. Deferred revenue and remaining performance obligations indicate substantial contracted future revenue, with $370.4 million of performance obligations outstanding. Cellebrite also completed the acquisition of SCG Canada Inc., adding drone‑forensics technology via a $23.5 million intangible asset.
Cellebrite DI Ltd. executive Jewell Marcus, Global Chief Revenue Officer, reported selling 411 ordinary shares of Cellebrite DI Ltd. on August 12, 2026 at a weighted average price of $16.0678 per share. A footnote explains the shares were originally granted as RSUs on February 11, 2025 and that the disposition is associated with tax obligations arising from the RSU vesting, effectively a sale to cover taxes. After this transaction, Marcus directly holds 439,690 ordinary shares. The transaction was not marked as conducted under a Rule 10b5-1 trading plan.
Cellebrite DI Ltd. executive David Nicholas Gee, Chief Marketing Officer, reported a sale of 230 ordinary shares of Cellebrite on August 12, 2026. The shares relate to restricted stock units granted on February 11, 2025, and the disposition is associated with the reporting person's tax obligations upon vesting of those RSUs. The weighted average sale price was $16.0678 per share, from multiple trades between $16.0086 and $16.08. Following this transaction, Gee directly holds 141,802 ordinary shares of Cellebrite.
Cellebrite DI Ltd. appointed Shiven Ramji, previously President, Products and Technology, as Chief Executive Officer and Board member, succeeding Thomas E. Hogan in a planned transition effective immediately.
For the quarter ended June 30, 2026, Cellebrite reported revenue of $131,138 thousand, up from $113,276 thousand a year earlier, with gross profit of $105,931 thousand and a gross margin of 80.8%. GAAP operating income was $6,949 thousand and net income was $6,371 thousand, while non-GAAP operating income reached $29,805 thousand and adjusted EBITDA was $31,790 thousand, a 24.2% adjusted EBITDA margin. Cash and cash equivalents were $141,250 thousand and total assets $994,311 thousand.
Management stated that annual recurring revenue (ARR) was below expectations due to longer sales cycles and slower expansion from Inseyets conversions and therefore lowered full-year 2026 ARR and revenue outlook. For full-year 2026, Cellebrite now expects ARR of $550–$560 million with 14–16% annual growth, revenue of $555–$561 million with 17–18% annual growth, and raised its adjusted EBITDA target to $153–$159 million, implying an adjusted EBITDA margin of about 28%.
Cellebrite Di Ltd. filed a notice that Thomas E. Hogan intends to sell ordinary shares, par value NIS 0.00001, through Morgan Stanley Smith Barney LLC on or around 08/12/2026, with trading on Nasdaq. The shares to be sold were acquired from Cellebrite Di Ltd. on 08/11/2026 as Performance Shares granted as employee compensation. During the prior three months, Hogan sold ordinary shares on 07/02/2026, with 103,188 shares reported sold for total consideration of 1625892.04.
Cellebrite DI Ltd. affiliate David Gee filed to sell ordinary shares, par value NIS 0.00001, of Cellebrite DI Ltd. on Nasdaq. The planned sale covers 653 shares through Morgan Stanley Smith Barney LLC, connected to restricted share units that vested under an S-8 registered compensation plan.
Over the prior three months, David Gee reported sales of 228 shares, 2,243 shares, and 3,430 shares of the same class of ordinary shares, each with corresponding aggregate dollar values listed.
Cellebrite DI Ltd. insider Marcus Jewell has indicated an intent to sell up to 1,045 ordinary shares of the company’s stock through Morgan Stanley Smith Barney LLC. These shares relate to restricted share units that vested on August 11, 2026 under an S-8 registered compensation plan.
In the prior three months, Jewell reported selling 383 ordinary shares on May 12, 2026 for $4,982.83 and 12,658 ordinary shares on May 18, 2026 for $161,656.58.